Logo image of DXR

DAXOR CORP (DXR) Stock Fundamental Analysis

NASDAQ:DXR - US2394671034 - Common Stock

11.06 USD
-0.27 (-2.38%)
Last: 9/5/2025, 8:09:13 PM
Fundamental Rating

3

DXR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. While DXR seems to be doing ok healthwise, there are quite some concerns on its profitability. DXR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year DXR was profitable.
DXR had a positive operating cash flow in the past year.
DXR had positive earnings in 4 of the past 5 years.
DXR had negative operating cash flow in 4 of the past 5 years.
DXR Yearly Net Income VS EBIT VS OCF VS FCFDXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

1.2 Ratios

With a decent Return On Assets value of 1.46%, DXR is doing good in the industry, outperforming 74.74% of the companies in the same industry.
DXR has a better Return On Equity (1.50%) than 73.16% of its industry peers.
Industry RankSector Rank
ROA 1.46%
ROE 1.5%
ROIC N/A
ROA(3y)6.45%
ROA(5y)5.61%
ROE(3y)6.73%
ROE(5y)6.34%
ROIC(3y)N/A
ROIC(5y)N/A
DXR Yearly ROA, ROE, ROICDXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

Looking at the Profit Margin, with a value of 447.75%, DXR belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
In the last couple of years the Profit Margin of DXR has declined.
The Operating Margin and Gross Margin are not available for DXR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 447.75%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-35.84%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DXR Yearly Profit, Operating, Gross MarginsDXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

More info and screens

4

2. Health

2.1 Basic Checks

DXR has more shares outstanding than it did 1 year ago.
DXR has more shares outstanding than it did 5 years ago.
DXR has a better debt/assets ratio than last year.
DXR Yearly Shares OutstandingDXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
DXR Yearly Total Debt VS Total AssetsDXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

DXR has an Altman-Z score of 39.99. This indicates that DXR is financially healthy and has little risk of bankruptcy at the moment.
DXR has a better Altman-Z score (39.99) than 98.95% of its industry peers.
DXR has a debt to FCF ratio of 28.40. This is a negative value and a sign of low solvency as DXR would need 28.40 years to pay back of all of its debts.
The Debt to FCF ratio of DXR (28.40) is better than 68.95% of its industry peers.
DXR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, DXR is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 28.4
Altman-Z 39.99
ROIC/WACCN/A
WACCN/A
DXR Yearly LT Debt VS Equity VS FCFDXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

DXR has a Current Ratio of 0.02. This is a bad value and indicates that DXR is not financially healthy enough and could expect problems in meeting its short term obligations.
DXR's Current ratio of 0.02 is on the low side compared to the rest of the industry. DXR is outperformed by 98.95% of its industry peers.
A Quick Ratio of 0.02 indicates that DXR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.02, DXR is doing worse than 98.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
DXR Yearly Current Assets VS Current LiabilitesDXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 574.51% over the past year.
Measured over the past years, DXR shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -54.84% on average per year.
The Revenue for DXR has decreased by -26.28% in the past year. This is quite bad
DXR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.63% yearly.
EPS 1Y (TTM)574.51%
EPS 3Y-54.84%
EPS 5YN/A
EPS Q2Q%-26.11%
Revenue 1Y (TTM)-26.28%
Revenue growth 3Y-24.67%
Revenue growth 5Y-20.63%
Sales Q2Q%-41.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DXR Yearly Revenue VS EstimatesDXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
DXR Yearly EPS VS EstimatesDXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 0.02 0.04 0.06 0.08

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 65.06, which means the current valuation is very expensive for DXR.
Based on the Price/Earnings ratio, DXR is valued a bit cheaper than the industry average as 66.84% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of DXR to the average of the S&P500 Index (27.06), we can say DXR is valued expensively.
Industry RankSector Rank
PE 65.06
Fwd PE N/A
DXR Price Earnings VS Forward Price EarningsDXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

64.74% of the companies in the same industry are more expensive than DXR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2134.54
EV/EBITDA N/A
DXR Per share dataDXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DXR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAXOR CORP

NASDAQ:DXR (9/5/2025, 8:09:13 PM)

11.06

-0.27 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)03-04 2026-03-04
Inst Owners1.96%
Inst Owner Change12.21%
Ins Owners5.44%
Ins Owner Change0.11%
Market Cap54.86M
Analysts80
Price Target23.97 (116.73%)
Short Float %2.58%
Short Ratio1.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6%
PT rev (3m)-6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 65.06
Fwd PE N/A
P/S 457.91
P/FCF 2134.54
P/OCF 2134.54
P/B 1.53
P/tB 1.53
EV/EBITDA N/A
EPS(TTM)0.17
EY1.54%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY0.05%
OCF(TTM)0.01
OCFY0.05%
SpS0.02
BVpS7.22
TBVpS7.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.46%
ROE 1.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 447.75%
GM N/A
FCFM 21.45%
ROA(3y)6.45%
ROA(5y)5.61%
ROE(3y)6.73%
ROE(5y)6.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-35.84%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 28.4
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 4.79%
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z 39.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)574.51%
EPS 3Y-54.84%
EPS 5YN/A
EPS Q2Q%-26.11%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.28%
Revenue growth 3Y-24.67%
Revenue growth 5Y-20.63%
Sales Q2Q%-41.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-75.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y100.7%
FCF growth 3YN/A
FCF growth 5Y-61.68%
OCF growth 1Y100.7%
OCF growth 3YN/A
OCF growth 5Y-61.68%